Clinical trial
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or…
NCT00034125 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00034125 |
|---|---|
| Title | Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. |
| Official title | a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | LY353381, tamoxifen |
| First posted | Apr 24, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | Argentina, Chile, India, Mexico, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: